26 March 2026: Aker BioMarine ASA today publishes its Annual Report for 2025,
which includes the annual accounts, the sustainability statement and the
auditor’s report for 2025.<\/p>\n
The report is attached and is also available at www.akerbiomarine.com.<\/p>\n
Aker BioMarine ASA has also published its annual financial statements in
European
Single Electronic Format (ESEF), available as an attachment to this release.<\/p>\n
For further information, please contact
Christopher Robin Vinter, SVP Finance
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com <\/p>\n
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.<\/p>\n
About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.<\/p>\n","protected":false},"excerpt":{"rendered":"26 March 2026: Aker BioMarine ASA today publishes its Annual Report for 2025,which includes the annual accounts, the…\n","protected":false},"author":2,"featured_media":47949,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[85],"tags":[25747,28212,28213,157,156,2255,377,28214],"class_list":{"0":"post-50737","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-oslo","8":"tag-moicco","9":"tag-moicco35","10":"tag-moicco3510","11":"tag-norway","12":"tag-oslo","13":"tag-regulatory","14":"tag-report","15":"tag-yearend"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116308452515823654","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/50737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=50737"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/50737\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/47949"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=50737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=50737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=50737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}